AIM ImmunoTech (AIM) 10-Q 12 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	May 10, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-27072
Entity Registrant Name	AIM IMMUNOTECH INC.
Entity Central Index Key	0000946644
Entity Tax Identification Number	52-0845822
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2117 SW Highway 484
Entity Address, City or Town	Ocala
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	34473
City Area Code	(352)
Local Phone Number	448-7797
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	AIM
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		48,408,295

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 23,395	$ 27,053
Marketable securities	7,454	7,137
Funds receivable from New Jersey net operating loss	1,763	1,676
Prepaid expenses and other current assets	548	455
Total current assets	33,160	36,321
Property and equipment, net	155	195
Right of use asset, net	792	829
Patent and trademark rights, net	1,898	1,941
Other assets	1,457	1,202
Total assets	37,462	40,488
Current liabilities:
Accounts payable	963	377
Accrued expenses	696	806
Current portion of operating lease liability	178	178
Total current liabilities	1,837	1,361
Long-term liabilities:
Operating lease liability	636	659
Commitments and contingencies (Notes 12 and 13)
Stockholders’ equity:
Series B Convertible Preferred Stock, stated value $1,000 per share, 692 and 696 issued and outstanding, respectively	692	696
Common Stock, par value $0.001 per share, authorized 350,000,000 shares, 48,407,326 and 48,084,287 issued and outstanding, respectively	48	48
Additional paid-in capital	418,456	418,270
Accumulated deficit	(384,207)	(380,546)
Total stockholders’ equity	34,989	38,468
Total liabilities and stockholders’ equity	$ 37,462	$ 40,488

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	48,407,326	48,084,287
Common stock, shares outstanding	48,407,326	48,084,287
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 1,000	$ 1,000
Preferred stock, shares issued	692	696
Preferred stock, shares outstanding	692	696

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues:
Clinical treatment programs – US	$ 49	$ 33
Total Revenues	49	33
Costs and Expenses:
Production costs		77
Research and development	2,052	1,036
General and administrative	2,292	2,072
Total Costs and Expenses	4,344	3,185
Operating loss	(4,295)	(3,152)
Gain (Loss) on investments	203	(934)
Interest and other income	199	45
Redeemable warrants valuation adjustment		31
(Loss) on sale of assets	(23)
Gain from sale of income tax operating losses	255	190
Net Loss	$ (3,661)	$ (3,820)
Basic and diluted loss per share	$ (0.08)	$ (0.08)
Weighted average shares outstanding basic and diluted	48,399,950	47,994,672

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021		$ 48	$ 417,217		$ (361,101)	$ 56,879
Balance, shares at Dec. 31, 2021	715	47,994,672
Equity based compensation			242			242
Net comprehensive loss					(3,820)	(3,820)
Balance at Mar. 31, 2022		$ 48	417,459		(364,921)	53,301
Balance, shares at Mar. 31, 2022	715	47,994,672
Balance at Dec. 31, 2021		$ 48	417,217		(361,101)	56,879
Balance, shares at Dec. 31, 2021	715	47,994,672
Balance at Dec. 31, 2022		$ 48	418,270		(380,546)	38,468
Balance, shares at Dec. 31, 2022	696	48,084,287
Common Stock issuance, net of costs			100			$ 100
Common stock issuance, net of costs, shares		323,039				969
Equity based compensation			82			$ 82
Series B preferred shares converted to common			4
Series B preferred shares converted to Common, shares	(4)
Net comprehensive loss					(3,661)	(3,661)
Balance at Mar. 31, 2023		$ 48	$ 418,456		$ (384,207)	$ 34,989
Balance, shares at Mar. 31, 2023	692	48,407,326

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (3,661)	$ (3,820)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	11	10
Redeemable warrants valuation adjustment		(31)
Amortization of patent, trademark rights	36	19	$ 218
Changes in ROU assets	37	5
Loss on available for sale marketable securities		19
Gain from sale of income tax operating losses	(255)	(190)
Equity-based compensation	82	242
Unrealized loss (gain) on marketable securities	(203)	915
Change in assets and liabilities:
Prepaid expenses and other current assets and other non current assets	(180)	8
Lease liability	(23)	(5)
Accounts payable	586	180
Accrued expenses	(110)	(110)
Net cash used in operating activities	(3,680)	(2,758)
Cash flows from investing activities:
Proceeds from sale of marketable securities	598	407
Purchase of patent and trademark rights	7	(33)
Purchase of marketable securities	(712)	(720)
Proceeds from sales of property and equipment	29
Net cash used in investing activities	(78)	(346)
Cash flows from financing activities:
Proceeds from sale of stock, net of issuance costs	100
Net cash provided by financing activities	100
Net decrease in cash and cash equivalents	(3,658)	(3,104)
Cash and cash equivalents at beginning of period	27,053	32,093	32,093
Cash and cash equivalents at end of period	23,395	28,989	$ 27,053
Supplemental disclosures of non-cash investing and financing cash flow information:
Conversion of Series B preferred	$ 4

Business and Basis of Presentat

Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	Note 1: Business and Basis of Presentation AIM ImmunoTech Inc. and its subsidiaries (collectively, “AIM”, “Company”, “we” or “us”) are an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. AIM’s flagship products are Ampligen (rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection (Interferon Alfa-n3). Ampligen has not been approved by the FDA or marketed in the United States. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (“CFS”). The Company’s primary present business focus involves Ampligen. Ampligen is a double-stranded RNA (“dsRNA”) molecule being developed for globally important cancers, viral diseases and disorders of the immune system. The Company is currently proceeding primarily in four areas: ● Conducting a randomized, controlled study to evaluate efficacy and safety of Ampligen compared to a control group to treat locally advanced pancreatic cancer patients. ● Evaluating Ampligen in other cancers, as a potential therapy that modifies the tumor microenvironment with the goal of increasing anti-tumor responses to checkpoint inhibitors. ● Exploring Ampligen’s antiviral activities and potential use as a prophylactic or treatment for existing viruses, new viruses and mutated viruses thereof. ● Evaluating Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”) and fatigue and/or Post-COVID conditions of fatigue. The Company is prioritizing activities in an order related to the stage of development, with those clinical activities in oncology, ME/CFS and Post-COVID conditions having priority over antiviral experimentation. The Company intends that priority clinical work be conducted in trials authorized by the FDA or European Medicines Agency (“EMA”), which trials support commercial development. However, AIM’s antiviral experimentation is designed to accumulate additional preliminary data supporting their hypothesis that Ampligen is a powerful, broad-spectrum prophylaxis and early-onset therapeutic that may confer enhanced immunity and cross-protection. Accordingly, AIM will conduct antiviral programs in those venues most readily available including foreign venues and able to generate valid proof-of-concept data. AIM’s business plan requires one or more Contract Manufacturing Organizations (“CMO”) to produce Ampligen API. This includes utilizing Jubilant HollisterStier and Polysciences Inc. (“Polysciences”) for the manufacture of our Poly I and Poly C12U polynucleotides and associated test methods. While AIM believes it has sufficient Ampligen API to meet current needs, it is also continually exploring new efficiencies so as to maximize its ability to fulfill future obligations. In the opinion of management, all adjustments necessary for a fair presentation of its consolidated financial statements have been included. Such adjustments consist of normal recurring items. Interim results are not necessarily indicative of results for a full year. The interim consolidated financial statements and notes thereto are presented as permitted by the Securities and Exchange Commission (“SEC”), and do not contain certain information which will be included in the Company’s annual consolidated financial statements and notes thereto. These consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the years ended December 31, 2022 and 2021, contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed on March 31, 2023. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure (“GAAP”) of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent and trademark valuations, stock-based compensation calculations, building valuation, fair value of warrants, and contingency accruals.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Loss Per Share	Note 2: Net Loss Per Share Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Equivalent common shares, consisting of stock options and warrants which amounted to 2,522,390 2,453,782

Equity-Based Compensation

Equity-Based Compensation	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Equity-Based Compensation	Note 3: Equity-Based Compensation The fair value of each option and equity warrant award is estimated on the date of grant using a Black-Scholes-Merton option pricing valuation model. Expected volatility is based on the historical volatility of the price of the Company’s stock. The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical data to estimate expected dividend yield, expected life and forfeiture rates. During the three months ended March 31, 2023, there were no 150,000 Stock options activity during the three months ended March 31, 2023, was as follows: Stock option activity for employees: Schedule of Vest Stock Option Activity Number of Weighted Weighted Aggregate Outstanding January 1, 2023 2,020,214 $ 3.01 8.86 $ — Granted — — — — Forfeited — — — — Expired — — — — Outstanding March 31, 2023 2,020,214 $ 3.01 8.55 $ — Vested and expected to vest March 31, 2023 2,020,214 $ 3.01 8.55 $ — Exercisable March 31, 2023 1,752,888 $ 2.22 6.52 $ — Unvested stock option activity for employees: Schedule of Unvested Stock Option Activity Number of Weighted Weighted Aggregate Unvested January 1, 2023 392,326 $ 4.15 5.85 $ — Granted — — — — Expired — — — — Vested (125,000 ) 0.47 9.52 — Unvested March 31, 2023 267,326 $ 5.23 8.55 $ — Stock option activity for non-employees: Schedule of Vest Stock Option Activity Number of Weighted Weighted Aggregate Outstanding January 1, 2023 579,155 $ 3.09 7.93 $ — Granted — — — — Forfeited — — — — Expired — — — — Outstanding March 31, 2023 579,155 $ 3.09 8.36 $ — Vested and expected to vest March 31, 2023 579,155 $ 3.09 8.36 $ — Exercisable March 31, 2023 474,988 $ 2.76 5.75 $ — Unvested stock option activity for non-employees: Schedule of Unvested Stock Option Activity Number of Weighted Weighted Aggregate Unvested January 1, 2023 166,668 $ 4.05 9.49 $ — Granted — — 9.68 — Expired — — — — Vested (62,500 ) 0.32 — — Unvested March 31, 2023 104,168 $ 11.39 5.75 $ — Stock-based compensation expense was approximately $ 82,000 242,000 As of March 31, 2023, and 2022, respectively, there was approximately $ 134,000 729,000

Marketable Securities

Marketable Securities	3 Months Ended
	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Note 4: Marketable Securities Marketable securities consist of mutual funds. As of March 31, 2023 and December 31, 2022, it was determined that none of the marketable securities had an other-than-temporary impairment. As of March 31, 2023 and December 31, 2022, all securities were measured as Level 1 instruments of the fair value measurements standard (See Note 11: Fair Value). As of March 31, 2023, and December 31, 2022 the Company held $ 7,454,000 7,137,000 Mutual Funds classified as available for sale consisted of: March 31, 2023 Schedule of Available of Sale Securities Fair Short-Term Mutual Funds $ 7,454 $ 7,454 Totals $ 7,454 $ 7,454 March 31, 2023 Schedule of Equity Securities Securities - Net gains and losses recognized during the period on equity securities $ 290 Less: Net gains and losses recognized during the period on equity securities sold during the period (87 ) Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ 203 Mutual Funds classified as available for sale consisted of: December 31, 2022 (in thousands) Securities Fair Short-Term Mutual Funds $ 7,137 $ 7,137 Totals $ 7,137 $ 7,137 December 31, 2022 (in thousands) Securities Net losses recognized during the period on equity securities $ (1,679 ) Less: Net gains and losses recognized during the period on equity securities sold during the period (751 ) Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ (928 )

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Accrued Expenses	Note 5: Accrued Expenses Accrued expenses consist of the following: Schedule of Accrued Expenses March 31, 2023 December 31, 2022 (in thousands) March 31, 2023 December 31, 2022 Compensation $ 17 $ 1 Professional fees 378 492 Clinical trial expenses 209 110 Other expenses 92 203 Accrued expenses $ 696 $ 806

Property and Equipment, net

Property and Equipment, net	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, net	Note 6: Property and Equipment, net Schedule of Property and Equipment March 31, 2023 December 31, 2022 (in thousands) March 31, 2023 December 31, 2022 Furniture, fixtures, and equipment $ 2,204 $ 2,233 Less: accumulated depreciation (2,049 ) (2,038 ) Property and equipment, net $ 155 $ 195 Property and equipment are recorded at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, ranging from three to ten years. Depreciation expense for the three months ending March 31, 2023 and March 31, 2022 was $ 11,000 10,000 The Company made a strategic shift on in-house manufacturing and recorded an impairment of the facility in the amount of $ 1,800,000 3.7

Patents, and Trademark Rights,

Patents, and Trademark Rights, Net	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Patents, and Trademark Rights, Net	Note 7: Patents, and Trademark Rights, Net Schedule of Patents, Trademark Rights December 31, 2021 $ 1,974 Acquisitions 375 Abandonments (190 ) Amortization (218 ) December 31, 2022 $ 1,941 Abandonments (7 ) Amortization (36 ) March 31, 2023 $ 1,898 Patents and trademarks are stated at cost and are amortized using the straight-line method over an estimated useful life of 17 Amortization of patents and trademarks for each of the next five years and thereafter is as follows: Schedule of Amortization of Patents and Trademarks Year Ending December 31, 2023 $ 128 2024 167 2025 162 2026 160 2027 149 Thereafter 1,132 Total $ 1,898

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Stockholders’ Equity	Note 8: Stockholders’ Equity (a) Preferred Stock The Company is authorized to issue 5,000,000 0.01 250,000 8,000 1,000 The Company is authorized to issue 8,000 no 1,000 692 696 114 Pursuant to a registration statement relating to a rights offering declared effective by the SEC on February 14, 2019, AIM distributed to its holders of common stock and to holders of certain options and warrants as of February 14, 2019, at no charge, one non-transferable subscription right for each share of common stock held or deemed held on the record date. Each right entitled the holder to purchase one unit, at a subscription price of $ 1,000 1,000 8.80 114 8.80 five years 4,700,000 0 (b) Common Stock and Equity Finances The Company has authorized shares of 350,000,000 8,000,000 350,000,000 On July 7, 2020, the board of directors approved a plan pursuant to which all directors, officers, and employees could purchase from the Company up to an aggregate of $ 500,000 132,238 86,817 1.16 2.35 0.76 1.02 During the three months ended March 31, 2023, the Company issued a total of 322,583 0.31 100,000 During the twelve months ended December 31, 2022, the Company issued a total of 132,238 1.16 2.35 205,000 On September 27, 2019, the Company closed a public offering underwritten by A.G.P./Alliance Global Partners, LLC (the “Offering”) of (i) 1,740,550 7,148,310 8,888,860 266,665 0.90 0.99 0.899 4.99% 0.001 7,200,000 1,870,000 8,873,960 266,665 264,000 46,000 15,000 The 2018 Equity Incentive Plan, effective September 12, 2018, authorizes the grant of (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards. Initially, a maximum of 7,000,000 10 26,324 9.68 10 23 9.68 27,570 9.68 ten years 400,000 2.77 3.07 ten years 850,000 0.31 1.71 ten years 613,512 1.11 1.71 ten years As of March 31, 2023, and December 31, 2022, there were 48,407,326 48,084,287

Cash and Cash Equivalents

Cash and Cash Equivalents	3 Months Ended
	Mar. 31, 2023
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	Note 9 Cash and Cash Equivalents AIM considers all highly liquid interest-earning investments with a maturity of three months or less at the date of purchase to be cash equivalents.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2023
Recent Accounting Pronouncements
Recent Accounting Pronouncements	Note 10: Recent Accounting Pronouncements During the first quarter of 2023 accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Fair Value

Fair Value	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value	Note 11: Fair Value Fair Value The Company complies with the provisions of FASB ASC 820 “Fair Value Measurements” for its financial and non-financial assets and liabilities. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. The fair values of cash and cash equivalents, other assets, accounts payable and accrued expenses approximate their carrying values due to the short-term maturities of these items and are considered a Level 1 instrument of the fair value measurements standard The Company recomputes the fair value of the Warrants at the issuance date and the end of each quarterly reporting period. Such value computation includes subjective input assumptions that are consistently applied each period. If the Company were to alter its assumptions or the numbers input based on such assumptions, the resulting fair value could be materially different. The Company utilized the following assumptions to estimate the fair value of the April 2018 Warrants: Schedule of Assumptions to Estimate Fair Value of Warrants March 31, December 31, 2023 2022 Underlying price per share $ 0.43 $ 0.31 Exercise price per share $ 17.16 $ 17.16 Risk-free interest rate 4.90 % 4.74 % Expected holding period 0.57 0.81 Expected volatility 85 % 75 % Expected dividend yield — — The Company utilized the following assumptions to estimate the fair value of the March 2019 Warrants: March 31, December 31, 2023 2022 Underlying price per share $ 0.43 $ 0.31 Exercise price per share $ 8.80 $ 8.80 Risk-free interest rate 4.68 % 4.67 % Expected holding period 0.94 1.19 Expected volatility 75 % 70 % Expected dividend yield — — The significant assumptions using the Monte Carlo Simulation approach for valuation of the Warrants are: (i) Risk-Free Interest Rate (ii) Expected Holding Period (iii) Expected Volatility (iv) Expected Dividend Yield (v) Expected Probability of a Fundamental Transaction. 1. The Company only has one product that is FDA approved but is currently not available for commercial sales. 2. The Company will have to perform additional clinical trials for FDA approval of its flagship product. 3. Industry and market conditions continue to include uncertainty, adding risk to any transaction. 4. The nature of a life sciences company is heavily dependent on future funding and high fixed costs, including Research & Development. 5. The Company has minimal revenues streams which are insufficient to meet the funding needs for the cost of operations or construction at their manufacturing facility; and 6. The Company’s Rights Agreement and Executive Agreements make it less attractive to a potential buyer. With the above factors utilized in analysis of the likelihood of the Put’s potential Liability, the Company estimated the range of probabilities related to a Put right being triggered as: Schedule of Range of Probabilities Range of Probability Probability Low 0.5 % Medium 1.0 % High 5.0 % The Monte Carlo Simulation has incorporated a 5.0 (vi) Expected Timing of Announcement of a Fundamental Transaction. (vii) Expected 100 Day Volatility at Announcement of a Fundamental Transaction 100 (viii) Expected Risk-Free Interest Rate at Announcement of a Fundamental Transaction (ix) Expected Time Between Announcement and Consummation of a Fundamental Transaction. While the assumptions remain consistent from period to period (e.g., utilizing historical stock prices), the actual historical prices input for the relevant period input change. As of March 31, 2023 and December 31, 2022 there was no The Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. AIM categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: 1. Level 1 – Quoted prices are available in active markets for identical assets or liabilities at the reporting date. Generally, this includes debt and equity securities that are traded in an active market. 2. Level 2 – Observable inputs other than Level 1 prices such as quote prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Generally, this includes debt and equity securities that are not traded in an active market. 3. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or other valuation techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. As of March 31, 2023, the Company has classified the warrants with cash settlement features as Level 3. Management evaluates a variety of inputs and then estimates fair value based on those inputs. As discussed above, the Company utilized the Monte Carlo Simulation Model in valuing the warrants. The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as (in thousands): Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis As of March 31, 2023 Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 7,454 $ 7,454 $ — $ — Liabilities: Redeemable warrants $ — — — $ — As of December 31, 2022 Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 7,137 $ 7,137 $ — $ — Liabilities: Redeemable warrant $ — — — $ —

Leases

Leases	3 Months Ended
	Mar. 31, 2023
Leases
Leases	Note 12: Leases The Company leases office and storage space, and other equipment under non-cancellable operating leases with initial terms typically ranging from 1 5 At contract inception, utilizing the guidance of ASC 842 “ Leases The Company has elected to include both lease and non-lease components in the determination of lease payments. Payments made to a lessor for items such as taxes, insurance, common area maintenance, or other costs commonly referred to as executory costs, are also included in lease payments if they are fixed. The fixed portion of these payments are included in the calculation of the lease liability, while any variable portion is recognized as variable lease expenses as incurred. At lease inception, lease-related assets and liabilities are measured at the present value of future lease payments over the lease term. For leases that do not provide an implicit rate, the Company utilizes an estimated incremental borrowing rate based on market observations existing at lease inception to calculate the present value of future payments. Leased assets are disclosed as Right of Use assets on the Company’s consolidated balance sheet and are amortized over the expected useful life of the lease. Lease liabilities are separately disclosed as a current and non-current portion on the Company’s consolidated balance sheet. Short term leases with an initial term of 12 months or less are not presented on the balance sheet with expense recognized as incurred. The Company entered into a Lease Agreement for a term of five years September 14, 2020 1,415 On June 13, 2018, the Company entered into a Lease Agreement for a term of six years July 1, 2018 3,000 3 2,100 2,785 On May 1, 2019, the Company entered into a Lease Agreement for a term of three years May 1, 2019 3,000 2,500 2,850 May 1, 2023 On February 17, 2022, the Company entered into a Lease Agreement for a term of two years March 1, 2022 322 On June 16, 2022, the Company entered into a Lease Agreement for a term of five years July 1, 2022 5,210 3 15,630 18,118 On December 9, 2022, the Company entered into a Lease Agreement for a term of two years April 1, 2023 470 6 1,645 1,744 The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods when it is reasonably certain that the Company would exercise such options. The Company’s leases have remaining lease terms between 12 53 25 28 The Company’s weighted average incremental borrowing rate for its leases was 10 Future minimum lease payments as of March 31, 2023, are as follows: Schedule of Operating Lease Future Payments Year Ending December 31, 2023 $ 203 2024 242 2025 216 2026 200 2027 133 Less imputed interest (178 ) Total $ 815 As of March 31, 2023, the net balance of the right of use assets was $ 792,000 815,000 829,000 837,000 87,000 17,000

Research, Consulting and Supply

Research, Consulting and Supply Agreements	3 Months Ended
	Mar. 31, 2023
Research Consulting And Supply Agreements
Research, Consulting and Supply Agreements	Note 13: Research, Consulting and Supply Agreements The following represent companies with which AIM has active contracts that it paid toward in Q1 2023. Amarex Clinical Research LLC AIM has multiple contracts with Amarex Clinical Research LLC (“Amarex”) In the first Q1 2023, we paid $ 520,800 ● Pancreatic Cancer - In April 2022, AIM executed a work order with Amarex pursuant to which Amarex will manage a Phase 2 clinical trial in locally advanced pancreatic cancer patients designated AMP-270. Per the work order, AIM anticipates that the study will cost approximately $ 8.2 1.0 4.6 ○ In Q1 2023, we paid approximately $ 309,400 ● Post-COVID Conditions - On June 13, 2022, AIM executed a work order with Amarex, pursuant to which Amarex will manage a Phase 2 trial in patients with Post-COVID Conditions. It is planned that the study will be conducted at up to 10 sites in the United States. AIM is sponsoring the study. AIM anticipates that the study will cost approximately $ 4.4 125,470 2.4 ○ In Q1 2023, we paid approximately $ 211,400 hVIVO Services Limited In July 2021, the Company executed a Reservation and Start-Up Agreement (the “Agreement”) with hVIVO Services Limited (“hVIVO”), and subsequently signed a clinical trial agreement (“CTA”) in September. For the year ended December 3, 2021, the Company had incurred an expense and paid hVIVO approximately $ 2,340,000 60,000 Impatients N.V. In 2016, the Company entered into a five-year agreement (the “Impatients Agreement”) with Impatients, N.V. (“myTomorrows”), a Netherlands-based company, for the commencement and management of an EAP in Europe and Turkey (the “Territory”) related to ME/CFS. Pursuant to the agreement, myTomorrows, as our exclusive service provider and distributor in the Territory, is performing EAP activities. The agreement was automatically extended for a period of 12 months on May 20, 2021; automatically extended again for an additional period of 12 months on May 20, 2022; and will be automatically extended again on May 20, 2023. In Q1 2023, we paid $ 8,000 Jubilant HollisterStier Jubilant HollisterStier (“Jubilant”) is AIM’s authorized CMO for Ampligen for the approval in Argentina. In 2017, the Company entered into a purchase order with Jubilant pursuant to which Jubilant will manufacture batches of Ampligen® for the Company. Since the 2017 engagement of Jubilant, four lots of Ampligen consisting of more than 16,000 1,432,257 ○ In Q1 2023, there were no Pharmaceutics International Inc. In December 2020, AIM added Pharmaceutics International Inc. (“Pii”) as a “Fill & Finish” provider to enhance the Company’s capacity to produce the drug Ampligen. This addition amplifies AIM’s manufacturing capability by providing redundancy and cost savings. The contracts augment AIM’s existing fill and finish capacity. As agreed to in the Master Services Agreement, the terms of each of AIM’s projects with Pii will be negotiated separately and defined in individual Service Contracts. For the year ended December 31, 2022, the Company has incurred an expense and paid Pii approximately $ 278,000 ○ In Q1 2023, we paid approximately $ 9,300 Polysciences Inc. In April 2021, the Company approved a proposal from Polysciences Inc. (“Polysciences”) for the manufacture of our Poly I and Poly C12U polynucleotides and associated test methods at Polysciences’ Warrington, PA location to enhance our capacity to produce the polymer precursors to the drug Ampligen. The Company is working with Polysciences to negotiate and finalize both a Service Agreement and a Quality Agreement. For the year ended December 31, 2021, the Company has incurred an expense and paid Polysciences approximately $ 250,000 103,000 ○ In Q1 2023, there were no Yamasa Corporation The Company has utilized Yamasa Corporation (“Yamasa”) for the production of raw materials required to create polymer precursors to manufacture the drug Ampligen. In March 2023, we submitted a work order for $ 327,730 related to the purchase of these raw materials from Yamasa. These raw materials will be used in the manufacture of polymer precursors at Sterling. ○ In Q1 2023, there were no payments related to Yamasa. Sterling Pharma Solutions On December 5, 2022, the Company entered into a Master Service Agreement and a Quality Agreement with Sterling Pharma Solutions (“Sterling”) for the manufacture of the Company’s Poly I and Poly C12U polynucleotides and transfer of associated test methods at Sterling’ Dudley, UK location to produce the polymer precursors to manufacture the drug Ampligen. ○ In Q1 2023, there were no

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 14: Subsequent Events On April 4, 2023, the “Company executed an Unrestricted Grant Agreement with Erasmus University Medical Center (“EUMC”) pursuant to which EUMC will use its best efforts to diligently carry out immune monitoring in pancreatic cancer patients. On April 5, 2023, the Company entered into a Consulting Agreement with Casper H.J. van Eijck, MD, PhD, pursuant to which, among other things, Dr. van Eijck will assist the Company in recruiting and assisting sites outside of the Netherlands to participate in clinical trials evaluating Ampligen for the treatment of pancreatic cancer. On April 19, 2023, we entered into an Equity Distribution Agreement (the “EDA”) with Maxim Group LLC (“Maxim”), pursuant to which the Company may sell, from time to time, shares of its common stock having an aggregate offering price of up to $ 8.5 3.0 During the quarter ended March 31, 2023, the Company did not sell any shares under the EDA. Subsequent to the end of Q1 2023, the Company sold 969 485 3 15 On May 9, 2023, the Company was granted a U.S. Patent for a method for preventing or reducing antigenic drift or viral reassortment in a host animal comprising determining if a host animal has been exposed to or infected by an avian influenza virus and administering to the exposed host animal alpha-interferon. On May 10, 2023, the Company filed a Certificate of Increase in Delaware, increasing the number of preferred stock designated as Series A Junior Participating Preferred Stock to 4,000,000 On May 12, 2023, the Company amended and restated its November 14, 2017 Rights Plan with American Stock Transfer & Trust Company as Rights Agent (the “Rights Plan”). Please see Item II, Part 5 “Other Information” for more details.

Equity-Based Compensation (Tabl

Equity-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Vest Stock Option Activity	Stock option activity for employees: Schedule of Vest Stock Option Activity Number of Weighted Weighted Aggregate Outstanding January 1, 2023 2,020,214 $ 3.01 8.86 $ — Granted — — — — Forfeited — — — — Expired — — — — Outstanding March 31, 2023 2,020,214 $ 3.01 8.55 $ — Vested and expected to vest March 31, 2023 2,020,214 $ 3.01 8.55 $ — Exercisable March 31, 2023 1,752,888 $ 2.22 6.52 $ —
Schedule of Unvested Stock Option Activity	Unvested stock option activity for employees: Schedule of Unvested Stock Option Activity Number of Weighted Weighted Aggregate Unvested January 1, 2023 392,326 $ 4.15 5.85 $ — Granted — — — — Expired — — — — Vested (125,000 ) 0.47 9.52 — Unvested March 31, 2023 267,326 $ 5.23 8.55 $ —
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Vest Stock Option Activity	Stock option activity for non-employees: Schedule of Vest Stock Option Activity Number of Weighted Weighted Aggregate Outstanding January 1, 2023 579,155 $ 3.09 7.93 $ — Granted — — — — Forfeited — — — — Expired — — — — Outstanding March 31, 2023 579,155 $ 3.09 8.36 $ — Vested and expected to vest March 31, 2023 579,155 $ 3.09 8.36 $ — Exercisable March 31, 2023 474,988 $ 2.76 5.75 $ —
Schedule of Unvested Stock Option Activity	Unvested stock option activity for non-employees: Schedule of Unvested Stock Option Activity Number of Weighted Weighted Aggregate Unvested January 1, 2023 166,668 $ 4.05 9.49 $ — Granted — — 9.68 — Expired — — — — Vested (62,500 ) 0.32 — — Unvested March 31, 2023 104,168 $ 11.39 5.75 $ —

Marketable Securities (Tables)

Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Schedule of Available of Sale	Mutual Funds classified as available for sale consisted of: March 31, 2023 Schedule of Available of Sale Securities Fair Short-Term Mutual Funds $ 7,454 $ 7,454 Totals $ 7,454 $ 7,454 December 31, 2022 (in thousands) Securities Fair Short-Term Mutual Funds $ 7,137 $ 7,137 Totals $ 7,137 $ 7,137
Schedule of Equity Securities	Schedule of Equity Securities Securities - Net gains and losses recognized during the period on equity securities $ 290 Less: Net gains and losses recognized during the period on equity securities sold during the period (87 ) Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ 203 Securities Net losses recognized during the period on equity securities $ (1,679 ) Less: Net gains and losses recognized during the period on equity securities sold during the period (751 ) Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ (928 )

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of the following: Schedule of Accrued Expenses March 31, 2023 December 31, 2022 (in thousands) March 31, 2023 December 31, 2022 Compensation $ 17 $ 1 Professional fees 378 492 Clinical trial expenses 209 110 Other expenses 92 203 Accrued expenses $ 696 $ 806

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Schedule of Property and Equipment March 31, 2023 December 31, 2022 (in thousands) March 31, 2023 December 31, 2022 Furniture, fixtures, and equipment $ 2,204 $ 2,233 Less: accumulated depreciation (2,049 ) (2,038 ) Property and equipment, net $ 155 $ 195

Patents, and Trademark Rights_2

Patents, and Trademark Rights, Net (Tables)	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Patents, Trademark Rights	Schedule of Patents, Trademark Rights December 31, 2021 $ 1,974 Acquisitions 375 Abandonments (190 ) Amortization (218 ) December 31, 2022 $ 1,941 Abandonments (7 ) Amortization (36 ) March 31, 2023 $ 1,898
Schedule of Amortization of Patents and Trademarks	Amortization of patents and trademarks for each of the next five years and thereafter is as follows: Schedule of Amortization of Patents and Trademarks Year Ending December 31, 2023 $ 128 2024 167 2025 162 2026 160 2027 149 Thereafter 1,132 Total $ 1,898

Fair Value (Tables)

Fair Value (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Assumptions to Estimate Fair Value of Warrants	The Company utilized the following assumptions to estimate the fair value of the April 2018 Warrants: Schedule of Assumptions to Estimate Fair Value of Warrants March 31, December 31, 2023 2022 Underlying price per share $ 0.43 $ 0.31 Exercise price per share $ 17.16 $ 17.16 Risk-free interest rate 4.90 % 4.74 % Expected holding period 0.57 0.81 Expected volatility 85 % 75 % Expected dividend yield — — The Company utilized the following assumptions to estimate the fair value of the March 2019 Warrants: March 31, December 31, 2023 2022 Underlying price per share $ 0.43 $ 0.31 Exercise price per share $ 8.80 $ 8.80 Risk-free interest rate 4.68 % 4.67 % Expected holding period 0.94 1.19 Expected volatility 75 % 70 % Expected dividend yield — —
Schedule of Range of Probabilities	Schedule of Range of Probabilities Range of Probability Probability Low 0.5 % Medium 1.0 % High 5.0 %
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as (in thousands): Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis As of March 31, 2023 Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 7,454 $ 7,454 $ — $ — Liabilities: Redeemable warrants $ — — — $ — As of December 31, 2022 Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 7,137 $ 7,137 $ — $ — Liabilities: Redeemable warrant $ — — — $ —

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2023
Leases
Schedule of Operating Lease Future Payments	Future minimum lease payments as of March 31, 2023, are as follows: Schedule of Operating Lease Future Payments Year Ending December 31, 2023 $ 203 2024 242 2025 216 2026 200 2027 133 Less imputed interest (178 ) Total $ 815

Net Loss Per Share (Details Nar

Net Loss Per Share (Details Narrative) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from earnings per share	2,522,390	2,453,782

Schedule of Vest Stock Option A

Schedule of Vest Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Outstanding, Beginning of Period | shares	2,020,214
Weighted Average Exercise Price Outstanding, Beginning of Period | $ / shares	$ 3.01
Weighted Average Remaining Contracted Term (years) Outstanding	8 years 10 months 9 days
Aggregate Intrinsic Value Outstanding, Beginning of Period | $
Number of Options, Granted | shares
Weighted Average Exercise Price, Granted | $ / shares
Aggregate Intrinsic Value, Granted | $
Number of Options, Forfeited | shares
Weighted Average Exercise Price, Forfeited | $ / shares
Aggregate Intrinsic Value, Forfeited | $
Number of Options, Expired | shares
Weighted Average Exercise Price, Expired | $ / shares
Aggregate Intrinsic Value, Expired | $
Number of Options Outstanding, Ending of Period | shares	2,020,214
Weighted Average Exercise Price Outstanding, End of Period | $ / shares	$ 3.01
Weighted Average Remaining Contracted Term (years) Outstanding	8 years 6 months 18 days
Aggregate Intrinsic Value Outstanding, Ending of Period | $
Number of Options, Vested and Expected to Vest | shares	2,020,214
Weighted Average Exercise Price, Vested and Expected to Vest | $ / shares	$ 3.01
Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest	8 years 6 months 18 days
Aggregate Intrinsic Value, Vested and Expected to Vest | $
Number of Options Exercisable, End of Period | shares	1,752,888
Weighted Average Exercise Price Exercisable, Ending of Period | $ / shares	$ 2.22
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period	6 years 6 months 7 days
Aggregate Intrinsic Value, Exercisable at End of Period | $
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Outstanding, Beginning of Period | shares	579,155
Weighted Average Exercise Price Outstanding, Beginning of Period | $ / shares	$ 3.09
Weighted Average Remaining Contracted Term (years) Outstanding	7 years 11 months 4 days
Aggregate Intrinsic Value Outstanding, Beginning of Period | $
Number of Options, Granted | shares
Weighted Average Exercise Price, Granted | $ / shares
Aggregate Intrinsic Value, Granted | $
Number of Options, Forfeited | shares
Weighted Average Exercise Price, Forfeited | $ / shares
Number of Options Outstanding, Ending of Period | shares	579,155
Weighted Average Exercise Price Outstanding, End of Period | $ / shares	$ 3.09
Weighted Average Remaining Contracted Term (years) Outstanding	8 years 4 months 9 days
Aggregate Intrinsic Value Outstanding, Ending of Period | $
Number of Options, Vested and Expected to Vest | shares	579,155
Weighted Average Exercise Price, Vested and Expected to Vest | $ / shares	$ 3.09
Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest	8 years 4 months 9 days
Aggregate Intrinsic Value, Vested and Expected to Vest | $
Number of Options Exercisable, End of Period | shares	474,988
Weighted Average Exercise Price Exercisable, Ending of Period | $ / shares	$ 2.76
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period	5 years 9 months
Aggregate Intrinsic Value, Exercisable at End of Period | $
Aggregate Intrinsic Value, Forfeited | $
Number of Options, Expired | shares
Weighted Average Exercise Price, Expired | $ / shares
Aggregate Intrinsic Value, Expired | $

Schedule of Unvested Stock Opti

Schedule of Unvested Stock Option Activity (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Granted	0	150,000
Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Unvested, Beginning of Period	392,326
Weighted Average Exercise Price Unvested, Beginning of Period	$ 4.15
Average Remaining Contractual Term (years) Unvested, Beginning of Period	5 years 10 months 6 days
Aggregate Intrinsic Value Unvested, Beginning of Period
Number of Options, Granted
Weighted Average Exercise Price, Granted
Aggregate Intrinsic Value, Granted
Number of Options, Expired
Weighted Average Exercise Price, Expired
Aggregate Intrinsic Value, Expired
Number of Options, Vested	(125,000)
Weighted Average Exercise Price, Vested	$ 0.47
Weighted Average Remaining Contracted Term (years) Vested	9 years 6 months 7 days
Aggregate Intrinsic Value, Vested
Number of Options Unvested, End of Period	267,326
Weighted Average Exercise Price Unvested, Ending of Period	$ 5.23
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period	8 years 6 months 18 days
Aggregate Intrinsic Value Unvested, End of Period
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Unvested, Beginning of Period	166,668
Weighted Average Exercise Price Unvested, Beginning of Period	$ 4.05
Average Remaining Contractual Term (years) Unvested, Beginning of Period	9 years 5 months 26 days
Aggregate Intrinsic Value Unvested, Beginning of Period
Number of Options, Granted
Weighted Average Exercise Price, Granted
Aggregate Intrinsic Value, Granted
Number of Options, Expired
Aggregate Intrinsic Value, Expired
Number of Options, Vested	(62,500)
Weighted Average Exercise Price, Vested	$ 0.32
Aggregate Intrinsic Value, Vested
Number of Options Unvested, End of Period	104,168
Weighted Average Exercise Price Unvested, Ending of Period	$ 11.39
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period	5 years 9 months
Aggregate Intrinsic Value Unvested, End of Period
Average Remaining Contractual Term granted	9 years 8 months 4 days

Equity-Based Compensation (Deta

Equity-Based Compensation (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options, granted	0	150,000
Share based compensation expense	$ 82,000	$ 242,000
Unrecognized stock-based compensation cost	$ 134,000	729,000
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options, granted
Share based compensation expense	$ 82,000	$ 242,000

Schedule of Available of Sale (

Schedule of Available of Sale (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Marketable Securities [Line Items]
Fair Value	$ 7,454	$ 7,137
Short-Term Investments	7,454	7,137
Mutual Funds [Member]
Marketable Securities [Line Items]
Fair Value	7,454	7,137
Short-Term Investments	$ 7,454	$ 7,137

Schedule of Equity Securities (

Schedule of Equity Securities (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Net losses recognized during the period on equity securities	$ 290	$ (1,679)
Less: Net gains and losses recognized during the period on equity securities sold during the period	(87)	(751)
Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date	$ 203	$ (928)

Marketable Securities (Details

Marketable Securities (Details Narrative) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Marketable securities	$ 7,454	$ 7,137

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Compensation	$ 17	$ 1
Professional fees	378	492
Clinical trial expenses	209	110
Other expenses	92	203
Accrued expenses	$ 696	$ 806

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, net	$ 155	$ 195
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Furniture, fixtures, and equipment	2,204	2,233
Less: accumulated depreciation	(2,049)	(2,038)
Property and equipment, net	$ 155	$ 195

Property and Equipment, net (De

Property and Equipment, net (Details Narrative) - USD ($) $ in Thousands		3 Months Ended		12 Months Ended
	Nov. 01, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation		$ 11	$ 10
Impairment charges				$ 1,800,000
Assets held for sale	$ 3,700	$ 29

Schedule of Patents, Trademark

Schedule of Patents, Trademark Rights (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Balance	$ 1,941,000	$ 1,974,000	$ 1,974,000
Acquisitions			375,000
Abandonments	(7)		(190)
Amortization	(36,000)	$ (19,000)	(218,000)
Balance	$ 1,898,000		$ 1,941,000

Schedule of Amortization of Pat

Schedule of Amortization of Patents and Trademarks (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 128
2024	167
2025	162
2026	160
2027	149
Thereafter	1,132
Total	$ 1,898	$ 1,941	$ 1,974

Patents, and Trademark Rights_3

Patents, and Trademark Rights, Net (Details Narrative)	Mar. 31, 2023
Patents and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and trademarks estimated useful life	17 years

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

12 Months Ended

Apr. 19, 2023

Jul. 07, 2020

Mar. 31, 2020

Sep. 27, 2019

Jan. 28, 2019

Nov. 14, 2018

Oct. 17, 2018

Sep. 12, 2018

Aug. 31, 2020

Mar. 31, 2023

Mar. 31, 2022

Dec. 31, 2021

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Class of Stock [Line Items]

Common stock, shares authorized

350,000,000

350,000,000

Common stock specific limitations and restrictions on usage

8,000,000

Common stock shares issued, value

$ 485

$ 100,000

Number of shares issued upon transaction

969

Proceeds from Issuance or Sale of Equity

$ 100,000

Warrant gross proceeds

$ 264,000

Warrant modification

$ 46,000

Warrant outstanding

15,000

Number of options granted

0

150,000

Common stock, shares outstanding

48,407,326

48,084,287

2018 Equity Incentive Plan [Member]

Class of Stock [Line Items]

Number of stock is reserved for potential issuance

7,000,000

Option vested years

10 years

Number of options granted

26,324

Option exercise price per share

$ 9.68

Pre-Funded Warrants [Member]

Class of Stock [Line Items]

Exercise price

$ 0.001

Shares issued price per share

$ 0.899

Percentage of outstanding stock

4.99%

Pre-funded warrants exercised

1,870,000

Warrant [Member]

Class of Stock [Line Items]

Exercise price

$ 0.99

Pre-funded warrants exercised

8,873,960

Alliance Global Partners, LLC [Member]

Class of Stock [Line Items]

Number of shares issued upon transaction

1,740,550

Warrants issued

7,148,310

Proceeds from Issuance or Sale of Equity

$ 7,200,000

Alliance Global Partners, LLC [Member] | Warrants [Member]

Class of Stock [Line Items]

Warrants exercised aggregate

8,888,860

Alliance Global Partners, LLC [Member] | Pre-Funded Warrants [Member]

Class of Stock [Line Items]

Shares issued price per share

$ 0.90

Maximum [Member] | Alliance Global Partners, LLC [Member] | Representative Warrants [Member]

Class of Stock [Line Items]

Warrants exercised aggregate

266,665

266,665

Directors, Officers and Employees [Member]

Class of Stock [Line Items]

Common stock shares issued, value

$ 500,000

Rights [Member]

Class of Stock [Line Items]

Exercise price

$ 1,000

Proceeds from warrants

$ 4,700,000

Warrant [Member]

Class of Stock [Line Items]

Exercise price

$ 8.80

Warrants and rights outstanding term

5 years

Series A Junior Participating Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares authorized

250,000

Series B Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares authorized

8,000

Preferred stock stated value

$ 1,000

$ 1,000

Preferred Stock, no par value

$ 0

Preferred stock, shares outstanding

692

696

Conversion of common stock

0

Series B Convertible Preferred Stock [Member] | Rights [Member]

Class of Stock [Line Items]

Preferred stock face value

$ 1,000

Preferred Stock [Member]

Class of Stock [Line Items]

Number of shares to be issued on conversion

114

Common Stock [Member]

Class of Stock [Line Items]

Common stock shares issued, value

$ 100,000

$ 205,000

Number of shares issued upon transaction

322,583

132,238

86,817

Shares issued price per share

$ 0.31

Common Stock [Member] | Minimum [Member]

Class of Stock [Line Items]

Shares issued price per share

$ 0.76

$ 1.16

$ 0.76

Common Stock [Member] | Maximum [Member]

Class of Stock [Line Items]

Shares issued price per share

$ 1.02

$ 2.35

$ 1.02

Board Of Directors [Member]

Class of Stock [Line Items]

Preferred stock, shares authorized

5,000,000

Preferred stock stated value

$ 0.01

Director [Member]

Class of Stock [Line Items]

Option vested years

10 years

Employees [Member] | 2018 Equity Incentive Plan [Member]

Class of Stock [Line Items]

Number of options granted

23

Option exercise price per share

$ 9.68

Officers [Member] | 2018 Equity Incentive Plan [Member]

Class of Stock [Line Items]

Number of options granted

27,570

400,000

Option exercise price per share

$ 9.68

Expiration period

10 years

10 years

Officers [Member] | Minimum [Member] | 2018 Equity Incentive Plan [Member]

Class of Stock [Line Items]

Option exercise price per share

$ 2.77

Officers [Member] | Maximum [Member] | 2018 Equity Incentive Plan [Member]

Class of Stock [Line Items]

Option exercise price per share

$ 3.07

Employees [Member] | 2018 Equity Incentive Plan [Member]

Class of Stock [Line Items]

Number of options granted

613,512

850,000

Expiration period

10 years

10 years

Employees [Member] | Minimum [Member] | 2018 Equity Incentive Plan [Member]

Class of Stock [Line Items]

Number of options granted

0.31

Option exercise price per share

$ 1.11

Employees [Member] | Maximum [Member] | 2018 Equity Incentive Plan [Member]

Class of Stock [Line Items]

Option exercise price per share

$ 1.71

$ 1.71

Schedule of Assumptions to Esti

Schedule of Assumptions to Estimate Fair Value of Warrants (Details)	Mar. 31, 2023 $ / shares	Dec. 31, 2022 $ / shares
April 2018 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Underlying price per share	$ 0.43	$ 0.31
April 2018 Warrants [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	17.16	17.16
April 2018 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	4.90	4.74
April 2018 Warrants [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant term	6 months 25 days	9 months 21 days
April 2018 Warrants [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	85	75
April 2018 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield
March 2019 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Underlying price per share	$ 0.43	$ 0.31
March 2019 Warrants [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	8.80	8.80
March 2019 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	4.68	4.67
March 2019 Warrants [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant term	11 months 8 days	1 year 2 months 8 days
March 2019 Warrants [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	75	70
March 2019 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield

Schedule of Range of Probabilit

Schedule of Range of Probabilities (Details)	3 Months Ended
	Mar. 31, 2023
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability	5%
Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability	0.50%
Weighted Average [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability	1%
Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability	5%

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	$ 7,454	$ 7,137
Redeemable warrants
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	7,454	7,137
Redeemable warrants
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities
Redeemable warrants
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities
Redeemable warrants

Fair Value (Details Narrative)

Fair Value (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Percentage of probability	5%
Floor rate used as proxy for future volatility percentage	100%
Fair value adjustment of warrants		$ (31,000)
Warrant [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value adjustment of warrants	$ 0		$ 0

Schedule of Operating Lease Fut

Schedule of Operating Lease Future Payments (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Leases
2023	$ 203,000
2024	242,000
2025	216,000
2026	200,000
2027	133,000
Less imputed interest	(178,000)
Total	$ 815,000	$ 837,000

Leases (Details Narrative)

Leases (Details Narrative)								3 Months Ended		12 Months Ended
	Dec. 09, 2022 USD ($) ft²	Oct. 05, 2022 USD ($)	Jun. 16, 2022 USD ($) ft²	Feb. 17, 2022 USD ($)	Sep. 14, 2020 USD ($)	May 01, 2019 USD ($) ft²	Jun. 13, 2018 USD ($) ft²	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Weighted average remaining term								25 months		28 months
Incremental borrowing rate								0.10		0.10
Right of use asset								$ 792,000		$ 829,000
Lease liability								815,000		$ 837,000
Short term lease rent expense								$ 87,000	$ 17,000
Lease Agreement [Member]
Lease agreement term	2 years		5 years			3 years	6 years
Lease commenced date	Apr. 01, 2023	May 01, 2023	Jul. 01, 2022			May 01, 2019	Jul. 01, 2018
Base rent per month					$ 1,415	$ 2,500
Rentable area | ft²	470		5,210			3,000	3,000
Percentage of base rent	6%		3%				3%
Payments for rent		$ 2,850
Lease Agreement [Member] | First Year [Member]
Base rent per month							$ 2,100
Operating Leases, Rent Expense, Net	$ 1,645		$ 15,630
Lease Agreement [Member] | Sixth Year [Member]
Base rent per month							$ 2,785
Lease Agreement [Member] | Fifth Year [Member]
Base rent per month	$ 1,744		$ 18,118
Lease Agreement [Member] | Fraser Advanced Information Systems [Member]
Lease agreement term					5 years
Lease commenced date					Sep. 14, 2020
Lease Agreement [Member] | Canon Copier [Member]
Lease agreement term				2 years
Lease commenced date				Mar. 01, 2022
Base rent per month				$ 322
Minimum [Member]
Operating lease term								1 year
Operating lease, remaining lease term								12 months
Maximum [Member]
Operating lease term								5 years
Operating lease, remaining lease term								53 months

Research, Consulting and Supp_2

Research, Consulting and Supply Agreements (Details Narrative)			1 Months Ended	3 Months Ended		12 Months Ended
	Jun. 13, 2022 USD ($)	Dec. 03, 2021 USD ($)	Apr. 30, 2022 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2017 Integer
Research and development expense				$ 2,052,000	$ 1,036,000
Amarex Clinical Research LLC [Member]
Research and development expense	$ 4,400,000		$ 1,000,000	520,800
Research and development expense			$ 8,200,000
Estimated lives			4 years 7 months 6 days
Development cost	125,470
Invigilators cost	$ 2,400,000
Amarex Clinical Research LLC [Member] | Pancreatic Cancer [Member]
Research and development expense				309,400
Amarex Clinical Research LLC [Member] | Post C O V I D [Member]
Research and development expense				211,400
H V I V O Services Limited [Member] | Reservation And Start Up Agreement [Member]
Research and development expense		$ 2,340,000
Cancellation fees					$ 60,000
Impatients N V [Member] | Research Consulting And Supply Agreements [Member]
Research and development expense				8,000
Jubilant Hollister Stier [Member]
Research and development expense | Integer								16,000
Research and development expense				1,432,257
Jubilant Hollister Stier [Member] | Research Consulting And Supply Agreements [Member]
Research and development expense				0
Pharmaceutics International, Inc [Member]
Research and development expense						$ 278,000
Pharmaceutics International, Inc [Member] | Research Consulting And Supply Agreements [Member]
Research and development expense				9,300
Polysciences Inc [Member]
Research and consulting				103,000			$ 250,000
Polysciences Inc [Member] | Research Consulting And Supply Agreements [Member]
Research and development expense				0
Yamasa Corporation [Member]
Research and development expense				327,730
Pharma Solutions [Member] | Master Service Agreement and Quality Agreement [Member]
Research and development expense				$ 0

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)		3 Months Ended
	Apr. 19, 2023	Mar. 31, 2023	May 10, 2023
Subsequent Event [Line Items]
Stock Issued During Period, Value, New Issues	$ 485	$ 100,000
Sale of Stock, Percentage of Ownership after Transaction	3%
Shares sold		969
Debt Instrument, Interest Rate, Stated Percentage		300%
Debt Instrument, Fee Amount		$ 15
Series A Junior Participating Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock, shares authorized		250,000
Series A Junior Participating Preferred Stock [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Preferred stock, shares authorized			4,000,000
Maxim Group L L C [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Value, New Issues	$ 8,500,000